215 related articles for article (PubMed ID: 21277963)
1. Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B.
Iman M; Huang Z; Szoka FC; Jaafari MR
Int J Pharm; 2011 Apr; 408(1-2):163-72. PubMed ID: 21277963
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution and
Iman M; Huang Z; Alavizadeh SH; Szoka FC; Jaafari MR
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630182
[TBL] [Abstract][Full Text] [Related]
3. Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis.
Abu Ammar A; Nasereddin A; Ereqat S; Dan-Goor M; Jaffe CL; Zussman E; Abdeen Z
Drug Deliv Transl Res; 2019 Feb; 9(1):76-84. PubMed ID: 30484256
[TBL] [Abstract][Full Text] [Related]
4. Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro.
Perez AP; Altube MJ; Schilrreff P; Apezteguia G; Celes FS; Zacchino S; de Oliveira CI; Romero EL; Morilla MJ
Colloids Surf B Biointerfaces; 2016 Mar; 139():190-8. PubMed ID: 26709977
[TBL] [Abstract][Full Text] [Related]
5. New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp.
Ruiz HK; Serrano DR; Dea-Ayuela MA; Bilbao-Ramos PE; Bolás-Fernández F; Torrado JJ; Molero G
Int J Pharm; 2014 Oct; 473(1-2):148-57. PubMed ID: 24998510
[TBL] [Abstract][Full Text] [Related]
6. Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.
Larabi M; Yardley V; Loiseau PM; Appel M; Legrand P; Gulik A; Bories C; Croft SL; Barratt G
Antimicrob Agents Chemother; 2003 Dec; 47(12):3774-9. PubMed ID: 14638481
[TBL] [Abstract][Full Text] [Related]
7. Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.
Jaafari MR; Hatamipour M; Alavizadeh SH; Abbasi A; Saberi Z; Rafati S; Taslimi Y; Mohammadi AM; Khamesipour A
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():156-165. PubMed ID: 31582344
[TBL] [Abstract][Full Text] [Related]
8. In vitro cytotoxicity of two novel oral formulations of Amphotericin B (iCo-009 and iCo-010) against Candida albicans, human monocytic and kidney cell lines.
Leon CG; Lee J; Bartlett K; Gershkovich P; Wasan EK; Zhao J; Clement JG; Wasan KM
Lipids Health Dis; 2011 Aug; 10():144. PubMed ID: 21854638
[TBL] [Abstract][Full Text] [Related]
9. Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes.
Prajapati VK; Awasthi K; Gautam S; Yadav TP; Rai M; Srivastava ON; Sundar S
J Antimicrob Chemother; 2011 Apr; 66(4):874-9. PubMed ID: 21393222
[TBL] [Abstract][Full Text] [Related]
10. Conjugation of amino-containing drugs to polysaccharides by tosylation: amphotericin B-arabinogalactan conjugates.
Ehrenfreund-Kleinman T; Golenser J; Domb AJ
Biomaterials; 2004 Jul; 25(15):3049-57. PubMed ID: 14967538
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome
Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Alavijeh M; Silva-Pedrosa R; Antunes S; Mauricio I; Murdan S; Croft SL
Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):223-228. PubMed ID: 29673889
[TBL] [Abstract][Full Text] [Related]
12. Bovine serum albumin nanoparticles containing amphotericin B were effective in treating murine cutaneous leishmaniasis and reduced the drug toxicity.
Casa DM; Scariot DB; Khalil NM; Nakamura CV; Mainardes RM
Exp Parasitol; 2018 Sep; 192():12-18. PubMed ID: 30026113
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation.
Gangadhar KN; Adhikari K; Srichana T
Int J Pharm; 2014 Aug; 471(1-2):430-8. PubMed ID: 24907597
[TBL] [Abstract][Full Text] [Related]
14. In-vitro and in-vivo antileishmanial activity of inexpensive Amphotericin B formulations: Heated Amphotericin B and Amphotericin B-loaded microemulsion.
Rochelle do Vale Morais A; Silva AL; Cojean S; Balaraman K; Bories C; Pomel S; Barratt G; do Egito EST; Loiseau PM
Exp Parasitol; 2018 Sep; 192():85-92. PubMed ID: 30075233
[TBL] [Abstract][Full Text] [Related]
15. A new nanoemulsion formulation improves antileishmanial activity and reduces toxicity of amphotericin B.
Santos DCMD; de Souza MLS; Teixeira EM; Alves LL; Vilela JMC; Andrade M; Carvalho MDG; Fernandes AP; Ferreira LAM; Aguiar MMG
J Drug Target; 2018 Apr; 26(4):357-364. PubMed ID: 29041824
[TBL] [Abstract][Full Text] [Related]
16. In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum.
Ordóñez-Gutiérrez L; Espada-Fernández R; Dea-Ayuela MA; Torrado JJ; Bolás-Fernandez F; Alunda JM
Int J Antimicrob Agents; 2007 Oct; 30(4):325-9. PubMed ID: 17631982
[TBL] [Abstract][Full Text] [Related]
17. Amphotericin B-Loaded Emulgel: Effect of Chemical Enhancers on the Release Profile and Antileishmanial Activity In Vitro.
Pinheiro IM; Carvalho IPS; Neto JAT; Lopes GLN; de Sousa Coêlho E; Sobrinho-Júnior EPC; de Moraes Alves MM; de Amorim Carvalho FA; Carvalho ALM
AAPS PharmSciTech; 2019 Feb; 20(3):122. PubMed ID: 30805739
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the in vivo leishmanicidal activity of amphotericin B emulgel: An alternative for the treatment of skin leishmaniasis.
Pinheiro IM; Carvalho IP; de Carvalho CE; Brito LM; da Silva AB; Conde Júnior AM; de Carvalho FA; Carvalho AL
Exp Parasitol; 2016 May; 164():49-55. PubMed ID: 26902606
[TBL] [Abstract][Full Text] [Related]
19. Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B.
Frankenburg S; Glick D; Klaus S; Barenholz Y
Antimicrob Agents Chemother; 1998 Dec; 42(12):3092-6. PubMed ID: 9835496
[TBL] [Abstract][Full Text] [Related]
20. Amphotericin B Loaded Nanostructured Lipid Carriers for Parenteral Delivery: Characterization, Antifungal and In vitro Toxicity Assessment.
Nimtrakul P; Tiyaboonchai W; Lamlertthon S
Curr Drug Deliv; 2019; 16(7):645-653. PubMed ID: 31362675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]